Saama Launches AI-Driven Data Platform
Suite of AI-enhanced SaaS solutions address many functions within clinical development.
Saama, a provider of AI- and ML-based solutions for clinical development and commercialization, announced its unified platform of SaaS-based products. By applying AI and advanced analytics to clinical development processes, Saama’s platform aims to eliminate manual, resource-intensive activities.
Saama uses more than 90 AI models built for life sciences, trained on over 300 million data points, which are embedded into the Saama platform. The platform includes the following solutions:
* Data Hub – to centralize and standardize clinical, operational, financial, and more data in a single location.
* Operational Insights – to provide a holistic view of trial operations to all team members and with visualizations of data including EDC, CTMS, and eTMF data.
* Patient Insights – to centralize and visualize patient data in a single location, and applies AI to patient data that can be used to predict patient behavior and track progress.
* Source to Submission (S2S) – automates the SDTM transformation process with AI/ML to simplify regulatory submissions.
* Smart Data Quality (SDQ) – automates data cleaning, review, and reconciliation processes for data managers to reduce query review.
Source: Saama Launches Industry’s First AI-driven Data Platform to Accelerate Clinical Development, June 20, 2023, BUSINESS WIRE.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
